- Molecular NameGlimepiride
- SynonymGlimepirid; Glimepirida; Glimepiridum; Glimepride
- Weight490.625
- Drugbank_IDDB00222
- ACS_NO93479-97-1
- Show 3D model
- LogP (experiment)3.306
- LogP (predicted, AB/LogP v2.0)4.86
- pkaN/A
- LogD (pH=7, predicted)3.02
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-3.13
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors3
- No.of HBond Acceptors9
- No.of Rotatable Bonds7
- TPSA133.06
- StatusFDA approved
- AdministrationN/A
- PharmacologyA medium-to-long acting sulfonylurea anti-diabetic drug.
- Absorption_value100.0
- Absorption (description)Glimepiride is completely absorbed after oral administration.
- Caco_2N/A
- Bioavailability95.0
- Protein binding99.5
- Volume of distribution (VD)0.18 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmGlimepiride is metabolized by CYP2C9 to an active (one-third potency) metabolite
- Half life5 h after single dose; 9 h after multiple doses.
- ExcretionAbout 40% of a dose is eliminated in faeces as metabolites and about 60% of a dose is eliminated in urine as metabolites.
- Urinary Excretion<0.5
- Clerance0.62 ml/min/kg
- ToxicitySevere hypoglycemic reactions with coma, seizure, or other neurological impairment
- LD50 (rat)N/A
- LD50 (mouse)LD50=mg/kg